Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

ABSTRACT:

Purpose of review

To review the most promising genetic markers associated with the variability in the safety or efficacy of warfarin and clopidogrel and highlight the verification and validation initiatives for translating clopidogrel and warfarin pharmacogenetic tests to clinical practice.

Recent findings

Rapid advances in pharmacogenetics, continuous decrease in genotyping cost, development of point-of-care devices and the newly established clinical genotyping programs at several institutions hold the promise of individualizing clopidogrel and warfarin based on genotype. Guidelines have been established to assist clinicians in prescribing clopidogrel or warfarin dose based on genotype. However, the clinical utility of clopidogrel and warfarin is still limited. Accordingly,

SUBMITTER: Shahin MH 

PROVIDER: S-EPMC3731766 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature